I'll side with Charles Daniels, Associate Dean Pharmacist in Charge UC San Diego, and the patients on this one.
https://www.congress.gov/bill/116th-congress/house-bill/1559/text"UC San Diego Health also hires an outside auditor to conduct an
annual review of our 340B program compliance. We provide regular
continuing education on 340B rule clarifications to our compliance
staff, our pharmacy personnel who work directly with patients at
the prescription counter.
Additionally, we tried to be very intentional about the phar-
macies with whom we contract. The 340B outpatient drug discount
is the lifeblood of so many services that UC San Diego Health pro-
vides to underserved patients.
Any efforts in rule making or legislation to scale back the 340B
Drug Pricing Program would be consequential to our patients and
the patients of safety net providers across the country."